Notable Labs to Present Data on September 4th at SOHO 2024
29 août 2024 07h30 HE
|
Notable Labs
Society of Hematologic Oncology (SOHO) session to highlight volasertib program Phase 2 volasertib AML program expected to begin in the coming months FOSTER CITY, Calif., Aug....
Notable Labs Announces CEO Transition
26 août 2024 16h05 HE
|
Notable Labs
Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 ...
Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study
24 juil. 2024 07h30 HE
|
Notable Labs
FOSTER CITY, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing new...
Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024
09 mai 2024 16h05 HE
|
Notable Labs
FOSTER CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing new...
Notable Labs Reports 2023 Financial Results and Provides a Business Update
12 avr. 2024 08h00 HE
|
Notable Labs
FOSTER CITY, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies...
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
09 avr. 2024 17h15 HE
|
Notable Labs
Poster outlines the parameters for developing a flow-cytometry-based PPMP as a companion diagnostic to predict volasertib responders, based on a proof-of-concept study using 41 primary acute myeloid...
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
08 avr. 2024 12h00 HE
|
Notable Labs
FOSTER CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer...
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
05 mars 2024 16h35 HE
|
Notable Labs
FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer...
Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment
22 févr. 2024 08h00 HE
|
Notable Labs
Predictive Precision Medicine Platform (PPMP) utilized to enrich program for clinically responding patients and reduce the risk, time, and cost of drug developmentVolasertib Phase 2 trial initiation...
Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome
18 déc. 2023 08h00 HE
|
Notable Labs; CicloMed, LLC
- PPMP Accurately Predicted Patient Outcomes in Fosciclopirox Phase 2a Leukemia Trial - - Predictive Results Further Advance PPMP and Corroborate Outcomes from 4 PPMP Validation Trials - - Furthers...